CONFERENCE SCHEDULE

THURSDAY, NOVEMBER 5, 2015

3:00 p.m.-4:30 p.m.
Educational Session 1: Immunotherapy 101
Veterans Memorial Auditorium

Co-Chairpersons: Jolanda de Vries, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands, and Mary L. (Nora) Disis, University of Washington, Seattle, WA

Immunity against cancer: How to be enhanced*
Jolanda de Vries

Gene-modified T cells as biotherapeutics for cancer*
Stephen Gottschalk, Baylor College of Medicine, Houston, TX

Immune checkpoint inhibitors: Opportunities and challenges
Mary L. (Nora) Disis

4:45 p.m.-6:15 p.m.
Educational Session 2: Mutation Profiling/Return of Genetic Data
Veterans Memorial Auditorium

Co-Chairpersons: Lee J. Helman, National Cancer Institute, Bethesda, MD, and Sharon E. Plon, Baylor College of Medicine, Houston, TX

Introduction
Lee J. Helman

National-scale cancer sequencing and treatment response data integration in The Netherlands*
Edwin Cuppen, University Medical Center Utrecht, Utrecht, The Netherlands

Assigning clinical meaning to genomic data for cancer precision medicine
Nikhil Wagle, Dana-Farber Cancer Institute, Boston, MA

Delivering on the promise of personalized medicine
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

Returning germline results to cancer patients*
Sharon E. Plon

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

Closing remarks
Sharon E. Plon

6:30 p.m.-8:00 p.m.
Opening Networking Reception
Grand/Liberty Ballroom, Sheraton Boston Hotel

FRIDAY, NOVEMBER 6, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Boylston Street Hallway

8:00 a.m.-8:05 a.m.
Welcome and Opening Remarks
Veterans Memorial Auditorium
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA
Lee J. Helman, National Cancer Institute, Bethesda, MD
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France

8:05 a.m.-9:35 a.m.
Keynote Lectures
Veterans Memorial Auditorium

Chairperson: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

Updates on engineered T cells as cancer therapies*
Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Impact of gut microbiota in cancer development and therapeutics
Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
9:35 a.m.-10:00 a.m.
Break
Boylston Street Hallway

10:00 a.m.-12:00 p.m.
Plenary Session 1: Cellular Immunotherapy
Veterans Memorial Auditorium

Co-Chairpersons: Alexander M. M. Eggermont, Institut Gustave-Roussy, Villejuif, France, and Crystal L. Mackall, National Cancer Institute, Bethesda, MD

Mutation-driven drug development (targeted agents) vs. immunotherapeutics development
Alexander M. M. Eggermont

CAR therapy for cancer: Emerging insights
Crystal L. Mackall

TIL therapy in the era of immune checkpoint blockade*
John B.A.G. Haanen, Netherlands Cancer Institute, Amsterdam, The Netherlands

Engineering T cells with introduced TCRs to effectively target tumors
Philip D. Greenberg, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA

12:00 p.m.-4:00 p.m.
Exhibit Show
Exhibit Hall C-D

12:15 p.m.-3:15 p.m.
Poster Session A
(not eligible for CME credit)
Exhibit Hall C-D

Angiogenesis and Antiangiogenesis Agents
Animal Models
Bioinformatics
Biomarkers

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

Cell Cycle Regulators
Chemoprevention
Clinical Trials
EGFR/Her2
Epigenetic Regulation of Tumor Immunity
Genomics, Proteomics, and Target Discovery
Imaging
Immune Modulators
In Vitro and In Vivo Models for Targets
Metastasis and Invasion
mTOR/PI3-Kinase
New Molecular Targets
Pediatric-Early Drug Development
Signal Transduction Modulators
Therapeutic Agents: Biological
Therapeutic Agents: Other
Therapeutic Agents: Small Molecule Kinase Inhibitors
Topoisomerase Inhibitors
Tubulin-Interacting Agents
Tumor Immunology Targets
Tumor Microenvironment
Late-Breaking Posters

12:15 p.m.-1:15 p.m.
AACR Chemistry in Cancer Research (CICR)
Working Group Town Hall Meeting
(not eligible for CME credit)
Room 210

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
3:30 p.m.-4:10 p.m.
Spotlight on Proffered Papers 1
(not eligible for CME credit)
Veterans Memorial Auditorium

Chairperson: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer*†
Giulia Siravegna, University of Torino - IRCCS Candiolo, Candiolo, Italy

Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology**†
Paul A. Clarke, Cancer Research UK Unit, The Institute of Cancer Research, London, United Kingdom

Novel ceritinib resistance mechanisms: New resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance*†
Ryohei Katayama, Japanese Foundation for Cancer Research, Tokyo, Japan

4:15 p.m.-6:15 p.m.
Concurrent Session 1: Radiomics: Imaging in the Context of Drug Development and Personalized Medicine
Ballroom B

Co-Chairpersons: Robert J. Gillies, Moffitt Cancer Center and Research Institute, Tampa, FL, and E. G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands

The radiology reading room of the future*
Robert J. Gillies

Incorporating molecular imaging methods in early drug development*
E. G. Elisabeth de Vries

Radiomics: The promise of imaging for personalized medicine
Hugo Aerts, Brigham and Women's Hospital, Boston, MA

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
†Short talk from proffered paper
Tumor growth rate (TGR) to identify pseudoprogression (PSPD) in cancer patients treated by anti-PD1 or anti-PD-L1
Charles Ferté, Institut Gustave-Roussy, Villejuif, France

4:15 p.m.-6:15 p.m.
Concurrent Session 2: Liquid Biopsies to Monitor Clonal Evolution and Drug Resistance
Veterans Memorial Auditorium

Co-Chairpersons: Alberto Bardelli, IRCC - University of Turin, Medical School, Candiolo, Italy, and Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Analysis of circulating tumor DNA to monitor clonal evolution
Muhammed Murtaza, Translational Genomics Research Institute, Phoenix, AZ

Comprehensive detection of structural alterations in the circulation of cancer patients*
(not eligible for CME credit)
Mark Sausen, Personal Genome Diagnostics, Baltimore, MD

Heterogeneity, drug resistance, and clonal dynamics in colorectal cancers*
Alberto Bardelli

Additional speaker to be announced

4:15 p.m.-6:15 p.m.
Concurrent Session 3: Handling Toxicities of Immune Checkpoints/Checkpoint Blockade
Ballroom A

Co-Chairpersons: Scott Gettinger, Yale University, New Haven, CT, and Antoine Italiano, Institute Bergonié, Bordeaux, France

Toxicities from immunomodulatory antibodies: An overview*
Antoine Italiano

Anti-PD-1/PD-L1 associated pneumonitis
Scott Gettinger

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
Dermatological toxicities from CTLA-4 and PD-1 immune checkpoint inhibition
Jennifer N. Choi, Yale University School of Medicine, New Haven, CT

Autoimmune endocrine disease induced with checkpoint inhibitors
Kevan Herold, Yale University School of Medicine, New Haven, CT

4:15 p.m.-6:15 p.m.
Concurrent Session 4: Therapeutic Vaccines
Ballroom C

Co-Chairpersons: James L. Gulley, National Cancer Institute, Bethesda, MD, and Daniel E. Speiser, Ludwig Cancer Research Center/University of Lausanne, Lausanne, Switzerland

Introduction
James L. Gulley

Targeting the epithelial-mesenchymal transition via brachyury-based cancer vaccines*
Claudia M. Palena, National Cancer Institute-CCR, Bethesda, MD

Developing personalized neoantigen-based cancer vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

DNA vaccines as treatment for prostate cancer:
Understanding mechanisms of resistance*
Douglas G. McNeel, University of Wisconsin-Madison, Madison, WI

Comprehensive analyses of tumor immunity with implications to cancer immunotherapies†
(not eligible for CME credit)
Bo Li, Dana-Farber Cancer Institute, Brookline, MA

Q&A/Discussion
Closing remarks
Daniel E. Speiser

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
†Short talk from proffered paper
CONFERENCE SCHEDULE

SATURDAY, NOVEMBER 7, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Boylston Street Hallway

8:00 a.m.-10:00 a.m.
Plenary Session 2: Immunotherapy Checkpoints
Veterans Memorial Auditorium

Co-Chairpersons: Paolo A. Ascierto, Istituto Nazionale Tumori, Naples, Italy, and Edward B. Garon, University of California-Los Angeles, Santa Monica, CA

What we learned from immunotherapy in previous years*
Paolo A. Ascierto

Progress in lung cancer treatment with immunotherapy*
Edward B. Garon

Combination with/of immunotherapies*
Christian Blank, Netherlands Cancer Institute, Amsterdam, The Netherlands

Biomarkers for response to PD-1/PD-L1 checkpoint blockade: PD-L1 and beyond
Janis M. Taube, Johns Hopkins University, Baltimore, MD

10:00 a.m.-10:20 a.m.
Break
Boylston Street Hallway

10:20 a.m.-12:20 p.m.
Plenary Session 3: Update on Targeting RAS and Cancer
Veterans Memorial Auditorium

Co-Chairpersons: Mariano Barbacid, Spanish National Cancer Research Center (CNIO), Madrid, Spain, and Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
Targeting K-RAS driven cancer*
Mariano Barbacid

Nontraditional chemical approaches to directly target K-RAS
Kevan M. Shokat, University of California-San Francisco/Howard Hughes Medical Institute, San Francisco, CA

K-RAS dependency in pancreatic cancer*
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Targeting K-RAS stemness
Frank McCormick

Drugging RAS into oblivion*
Gregory L. Verdine, Harvard University and Warp Drive Bio, Cambridge, MA

12:30 p.m.-4:00 p.m.
Exhibit Show
Exhibit Hall C-D

12:30 p.m.-3:30 p.m.
Poster Session B
(not eligible for CME credit)
Exhibit Hall C-D

Biomarkers
Cellular Responses to Therapy
Clinical Trials
Drug Delivery
Drug Design
Drug Resistance and Modifiers
Drug Screening
Epigenetic Targets
Heat Shock Proteins
Immune Checkpoints
Immune Monitoring/Clinical Correlates

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

MAPK pathways
Molecular Classification of Tumors
mTOR/PI3-Kinase
Natural Products
New Molecular Targets
Novel Assay Technology
Pharmacogenetics, Pharmacogenomics, and Therapeutic Response
Pharmacokinetics and Pharmacodynamics
Protein-Protein Interaction
Target Identification and Validation
Therapeutic Agents: Other
Therapeutic Agents: Small Molecule Kinase Inhibitors
Toxicology
Tumor Microenvironment
Other Topics
Late-Breaking Posters

2:00 p.m.-3:15 p.m.
Regulatory Science and Policy Session: How to Achieve Breakthrough Therapy Designation in Oncology
(not eligible for CME credit)

Speakers:
George D. Demetri, Dana-Farber Cancer Institute, Boston, MA
Dickran Kazandjian, U.S. Food and Drug Administration, Silver Springs, MD
Eric H. Rubin, Merck Research Laboratories, North Wales, PA
David Kerstein, ARIAD Pharmaceuticals, Inc., Cambridge, MA

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
3:45 p.m.-4:25 p.m.
Spotlight on Proffered Papers 2
(not eligible for CME credit)
Veterans Memorial Auditorium

Chairperson: Patricia M. LoRusso, Yale Cancer Center, New Haven, CT

Exceptional response to PD-1 antibody treatment in a POLE-mutant endometrial cancer*†
Janice M. Mehnert, Rutgers-The Cancer Institute of New Jersey, New Brunswick, NJ

Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors*†
Ryan J. Sullivan, Massachusetts General Hospital Cancer Center, Boston, MA

AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: A phase I study*†
Dae Ho Lee, Asan Medical Center, Seoul, Korea

4:30 p.m.-6:30 p.m.
Concurrent Session 5: Systems Biology
Ballroom A

Co-Chairpersons: Trey Ideker, University of California-San Diego, La Jolla, CA, and Walter Kolch, Systems Biology Ireland, Dublin, Ireland

The Cancer Cell Map Initiative*
Trey Ideker

From the cancer landscape to personalized treatment*
Lodewyk F. Wessels, Netherlands Cancer Institute, Amsterdam, The Netherlands

Personalized cancer diagnostics and therapeutics based on the computational modeling of signal transduction networks*
Walter Kolch

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
†Short talk from proffered paper
Serial killing of tumor cells by cytotoxic T cells: Mechanisms and implications for therapy*
Peter Friedl, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, and The University of Texas MD Anderson Cancer Center, Houston, TX
4:30 p.m.-6:30 p.m.
Concurrent Session 6: Advances in Targeting the Hormone Axis
Ballroom C
Co-Chairpersons: Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom, and Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA
Resistance mechanisms subverting the AR program in CRPC: Opportunities for new therapeutics
Peter S. Nelson
Regulation of AR variants by BET bromodomains in prostate cancer*
Scott M. Dehm, Masonic Cancer Center, University of Minnesota, Minneapolis, MN
Androgen receptor splice variants dimerize to regulate gene expression and promote castration-resistant cell growth*
Yan Dong, Tulane University, New Orleans, LA
ARV-330: An androgen receptor PROTAC degrader for prostate cancer*†
(not eligible for CME credit)
James D. Winkler, Arvinas, Inc., New Haven, CT
TAS3681, a new type androgen receptor antagonist, suppresses ligand-independent AR activation through its AR downregulation activity*†
(not eligible for CME credit)
Daisuke Kajiwara, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan
RAD1901, an orally available selective estrogen receptor downregulator, has potent antitumor activity in in vitro and in vivo models of ER+ breast cancer*†
(not eligible for CME credit)
Teeru Bihani, Radius Health, Waltham, MA

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
†Short talk from proffered paper
Combination strategies*
Johann S. De Bono

4:30 p.m.-6:30 p.m.  
Concurrent Session 7: Analysis of Single Cells  
Ballroom B

Co-Chairpersons: Caroline Dive, CRUK Manchester Institute, Manchester, United Kingdom, and Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA

Using CTCs to improve outcomes in SCLC: Single cell profiling, ex vivo cultures, and mouse models*
Caroline Dive

Fluid biopsy in prostate cancer, from biochemical relapse to castrate resistance
Peter Kuhn, University of Southern California, Los Angeles, CA

Microfluidic isolation and molecular analysis of single CTCs
Daniel A. Haber

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq*
Itay Tirosh, The Broad Institute of MIT and Harvard, Cambridge, MA

4:30 p.m.-6:30 p.m.  
Concurrent Session 8: Cancer Epigenetics and Metabolism  
Veterans Memorial Auditorium

Co-Chairpersons: Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY, and Roger Stupp, University Hospital Zürich, Zürich, Switzerland

Role of mutations in epigenetic regulators in pathogenesis of myeloid malignancies*
Ross L. Levine

Metabolic adaptations and liabilities of TCA cycle-truncated tumors*
Eyal Gottlieb, Cancer Research UK, Beatson Institute, Glasgow, United Kingdom

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

Title to be announced
Roger Stupp

Targeting super-enhancer driven transcriptional dependencies in cancer*
Rani E. George, Dana-Farber Cancer Institute, Boston, MA

6:00 p.m.-8:00 p.m.
AACR Women in Cancer Research (WICR)
Career Mentoring Session and Reception
(not eligible for CME credit)
Room 210

Co-Chairpersons: Patricia M. LoRusso, Yale Cancer Center, New Haven, CT, and Lillian L. Siu, Princess Margaret Cancer Center, Toronto, ON, Canada

Keynote Address:
Eyes wide open: Tips on preparing for a career in research
Joan S. Brugge, Harvard Medical School, Boston, MA

Roundtables with Mentors
See page 15 for details.

SUNDAY, NOVEMBER 8, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Boylston Street Hallway

8:00 a.m.-10:00 a.m.
Plenary Session 4: Advances in Targeted Therapy
Veterans Memorial Auditorium

Co-Chairpersons: José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY, and Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain

Targeting driving genomic mutations in breast cancer
José Baselga

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
Title to be announced
Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA

Basket studies: Lessons learned and future directions*
David Hyman, Memorial Sloan Kettering Cancer Center, New York, NY

Dissecting colorectal cancer in multiple targetable subtypes
Josep Tabernero

The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas*
Howard A. Burris, III, Sarah Cannon Research Institute, Nashville, TN

10:00 a.m.-10:20 a.m.
Break
Boylston Street Hallway

10:20 a.m.-12:20 p.m.
Plenary Session 5: Advances in Targeted DNA Repair
Veterans Memorial Auditorium

Co-Chairpersons: Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA, and Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France

ERCC1 alternative readouts*
Jean-Charles Soria

Synthetic lethal interaction between homologous recombination repair and POLQ-mediated alternative end-joining*
Alan D. D’Andrea

Exploiting cancer replication stress using pharmacological inhibitors of ATR and WEE1
Mark J. O’Connor, AstraZeneca, Cheshire, United Kingdom

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

PARP trapping versus PARP catalytic inhibition and coupling with TDPI*
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD

Phase 1 trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity*
Timothy A. Yap, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

12:30 p.m.-4:00 p.m.
Exhibit Show
Exhibit Hall C-D

12:30 p.m.-3:30 p.m.
Poster Session C
(not eligible for CME credit)
Exhibit Hall C-D
Apoptosis, Necrosis, and Autophagy
Biomarkers
Cancer Stem Cells
Cellular Responses to Therapy
Chemistry
Clinical Trials
DNA Repair and Modulation
Drug Metabolism, Transport, and Biodistribution
Drug Resistance and Modifiers
Epigenetic Targets
Gene Therapies
Hormonal Agents and Therapy
Immune Mechanisms Invoked by Radiation Therapy
Immune Response to Therapies
Metabolism

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
Monoclonal Antibodies
New Molecular Targets
Other Topics
Radiotherapeutics
RNA and RNA-based Technologies and Therapies
Target Identification and Validation
Therapeutic Agents: Biological
Therapeutic Agents: Other
Therapeutic Agents: Small Molecule Kinase Inhibitors
Tumor Suppressors
Immune Modulators
Late-Breaking Posters

3:45 p.m.-4:25 p.m.
Spotlight on Proffered Papers 3
(not eligible for CME credit)
Veterans Memorial Auditorium

Chairperson: Manuel Hidalgo, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

Phase 1 study of a novel PARP1/2 selective inhibitor, BGB-290**
Jason Yang, Nucleaus Network, Melbourne, Australia

Discovery and preclinical evaluation of cEt-modified KRAS antisense oligonucleotide inhibitors*†
Alexey S. Revenko, Isis Pharmaceuticals, Carlsbad, CA

Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions*†
David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
†Short talk from proffered paper
CONFERENCE SCHEDULE

4:30 p.m.-6:30 p.m.
Plenary Session 6: Resistance to Targeted Therapy
Veterans Memorial Auditorium

Co-Chairpersons: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, and Richard M. Marais, Cancer Research UK Manchester Institute, Manchester, United Kingdom

Identifying determinants of response and resistance to targeted therapy and immunotherapy
Levi A. Garraway

Mechanisms of resistance of targeted therapies in leukemia
John C. Byrd, The Ohio State University Wexner Medical Center, Columbus, OH

Targeting BCL2 family proteins to increase the efficacy of cancer therapies
Joan S. Brugge, Harvard Medical School, Boston, MA

Precision medicine protocols to circumvent resistance to targeted therapy in melanoma
Richard M. Marais

MONDAY, NOVEMBER 9, 2015

7:00 a.m.-8:00 a.m.
Continental Breakfast
Boylston Street Hallway

8:00 a.m.-10:00 a.m.
Plenary Session 7: Tumor Microenvironment
Veterans Memorial Auditorium

Co-Chairpersons: Marina Y. Konopleva, The University of Texas MD Anderson Cancer Center, Houston, TX, and Christophe Massard, Institut Gustave-Roussy, Villejuif, France

Altered metabolism in leukemic microenvironment*
Marina Y. Konopleva

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
Tumor hypoxia and radiation resistance: Anything new on the horizon?*
Eric Deutsch, Institut Gustave-Roussy, Villejuif, France

The multifaceted role of Notch signaling in tumor/microenvironment interaction*
Jon C. Aster, Brigham and Women’s Hospital, Boston, MA

Notch inhibitor in clinic
Christophe Massard

10:00 a.m.-10:20 a.m.
Break
Boylston Street Hallway

10:20 a.m.-12:20 p.m.
Plenary Session 8: The In Vitro Patient
Veterans Memorial Auditorium

Co-Chairpersons: James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, and Emile E. Voest, Netherlands Cancer Institute, Amsterdam, The Netherlands

Use of tumor organoids in personalized medicine
Emile E. Voest

NCI patient-derived models repository*
James H. Doroshow

Ovarian PDX models: Of Mice and (Wo)men... and personalized treatment*
Paul Haluska, Merck Research Laboratories, Rahway, NJ

High-throughput drug screens in cancer cell models to enable precision cancer medicine*
Mathew Garnett, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

12:20 p.m.-12:30 p.m.
Closing Remarks
(not eligible for CME credit)
Veterans Memorial Auditorium
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.